SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been selected to be one of the inaugural companies in the new NASDAQ® NeuroInsights® Neurotech Index. The index launched today and is calculated on a price return basis (NASDAQ:NERV) and a total return basis (NASDAQ:NRVX).
